RCSI University

News

An AI tool could identify colorectal cancer patients most likely to respond to bevacizumab, which was recently backed for NHS use.

R&D

Mike Cooke, CEO of AmacaThera, spoke with pharmaphorum at the LSX World Congress, including about non-opioid pain relief.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.